Hyperalgesia
|
0.380 |
AlteredExpression
|
phenotype |
BEFREE |
Both sympathetic and sensory denervation resulted in lower immunoreactivity against markers of proliferation and fibrosis, especially sensory denervation.In Experiment 2, surgical denervation before or after induction of endometriosis also decelerated the development of endometriosis, as manifested by significantly reduced lesion weight and extent of lesional fibrosis, along with improved hyperalgesia.In Experiment 3, NK1R activation by SP infusion accelerated lesional development, as evidenced by significantly increased lesional weight, more thorough progression of EMT, FMT, SMM, exaggerated lesional fibrosis and deteriorated hyperalgesia.
|
30689856 |
2019 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
Intravesical substance P caused profound referred hyperalgesia accompanied by little bladder swelling or edema 6-24 h after the administration, in contrast to i.p.
|
29407215 |
2018 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
We found that PRF in combination with NBT increased β-EP levels and decreased plasma IL-6 and SP, thereby alleviating pain and hyperalgesia in PHN patients.
|
29888123 |
2018 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
Here we performed long-term evaluation of allodynia and hyperalgesia in a CCI model, and evaluated the effects of NGF and SP on the peripheral and central nervous systems.
|
28685530 |
2017 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
CGRP and SP contribute to the development of peripheral hyperalgesia.
|
28337884 |
2017 |
Hyperalgesia
|
0.380 |
AlteredExpression
|
phenotype |
BEFREE |
Several studies have shown that activation of neurokinin-1 (NK-1) receptors in the RVM produces hyperalgesia, although the underlying mechanisms are not clear.
|
28794197 |
2017 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
Moreover, extracellular signal-regulated kinase, substance P, and neurokinin-1 are involved in formation of central hyperalgesia.
|
29089993 |
2017 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
Emerging evidence has suggested that neurokinin 1 receptor (NK1R) is important in the development of visceral pain and hyperalgesia, however, whether NK1R exists in the CSF‑CN and its exact role in visceral pain remain to be fully elucidated.
|
28440440 |
2017 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
In contrast, intrathecal substance P 100 nmol produced hyperalgesia, and intrathecal DAMGO 10 nmol produced antinociception.
|
19231294 |
2009 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia.
|
18234883 |
2008 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
Antinociceptive properties of mixture of alpha-amyrin and beta-amyrin triterpenes: evidence for participation of protein kinase C and protein kinase A pathways.
|
15626726 |
2005 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
In addition, the ME of B. microstachya (3--300 mg kg(-1), i.p., 30 min earlier) inhibited, in a graded manner, the hyperalgesia induced by bradykinin (3.2 microg/paw), substance P (13.5 microg/paw), carrageenan (300 microg/paw), capsaicin (100 microg/paw) and adrenaline (100 ng/paw) in the rat paw, with mean ID50 values of 20.5, 17.9, 101.8, 54.2 and 99.7 mg kg(-1), respectively.
|
16259764 |
2005 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain.
|
12787826 |
2003 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
Hyperalgesia during opioid abstinence: mediation by glutamate and substance p.
|
12351280 |
2002 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
GAEE significantly inhibited the hyperalgesia induced by bradykinin or substance P in rat paw, but did not affect the hyperalgesia caused by carrageenan or prostaglandin E2.
|
10499367 |
1999 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
The HE (3 to 100 mg kg(-1), p.o., 1 h) inhibited in a graded manner, the hyperalgesia induced by bradykinin (3 nmol/paw) or substance P (10 nmol/paw) in rat paw, with mean ED50 values of 54.5 and 53.7 mg kg(-1), respectively.
|
9714424 |
1998 |
Hyperalgesia
|
0.380 |
Biomarker
|
phenotype |
CTD_human |
Substance P and capsaicin-induced mechanical hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2 receptors.
|
8864563 |
1996 |